Guardian Unlimited
Go to:  
Guardian UnlimitedThe Guardian
Home UK Business Online World dispatch The Wrap Weblog Talk Search
The Guardian World News guide Arts Special reports Columnists Audio Help Quiz

UK news
 
  Search this site






  In this section
Fertility clinic planned for lesbian couples

Naked pictures force closure of gallery

Equitable directors snub report

PCs: the latest waste mountain

Shadow cast over boom in online betting

OS maps out the future

Footballers to be told charges they face

Test could cut exam stress for 7-year-olds

Detained leader offered to inform on extremists

The colour of a curry may make it look better - but is it good for you?

Divers sent to rescue Britons trapped in flooded Mexican cave system

Art prize show that's far from uniform

Husband confessed to breakfast murder in 999 call, court told

Mother of truant sent back to prison

In brief

Train operators want to control tracks

Mars rover finds itself at the seaside

Octopus's gardener: new view of breadwinner Beatle

No new evidence on Whitear death

Is this the worst-kept secret in television?

How the Queen's Fragonard saved Lennon's prints

FertilityLegal fight to save embryos

Credit cards may improve tax collection

Poll of most irritating phrases

Pensioner barred from town

Plan to demolish Alder Hey

Ski slope injuries 'hurt NHS'

Boost for new Billy Elliots

Judge's doubts on prosecution

Museum puts 'sinful' science on show

Where plastic bootees are de rigeur for visitors

US acts on drug suicide warning

Children's author 'groomed fans for assault and rape'

Family of Briton on death row appeals to Blair

'Bendy buses' withdrawn after fires

Black people 'feel more victimised by stop and search'

'We shall literally fight them on the beaches'

Mobile phone autism advertisement ruled offensive

Trapped cavers await British rescue


US acts on drug suicide warning

Sarah Boseley, health editor
Wednesday March 24, 2004
The Guardian


Prozac, Seroxat and other commonly used antidepressants of the same class must carry warnings that children and adults might become suicidal while taking them, the American drug regulator said yesterday, increasing the pressure on the UK to act.

The Food and Drug Administration (FDA) stopped short of stating that the drugs can cause some people to want to kill themselves, but made it clear it was a possibility. Doctors should be aware that if a patient's depression appeared to get worse, it "could be due to the underlying disease or might be a result of drug therapy", the FDA said.

David Healy, the consultant psychiatrist from north Wales who raised concerns about suicidal thoughts and the SSRI (selective serotonin reuptake inhibitors) class of drugs, said yesterday that the FDA announcement was very close to stating that the drugs caused the problems that have been reported.

"They won't use the 'cause' word all that quickly but they have said this happens during the early days of treatment and it also happens when you change the dose. That is as causal as you can get," he said.

"They are hedging their legal bets. Regulators are at real risk of being brought to the courts by pharmaceutical companies that are unhappy with what they have done."

An expert working group was set up by the UK drug regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), last year to investigate the allegations not only that the drugs made people suicidal and aggressive, but also that they suffered severe side-effects when they tried to stop taking them.

The group looked first at the clinical trial evidence relating to children and found that there were more suicides in those on SSRIs than on the placebo. As a result, the MHRA banned the use of all the drugs except Prozac by those under 18.

But the working group is still examining the evidence in adults. Richard Brook, chief executive of the mental health charity Mind, resigned last week from the group over the MHRA's reluctance to reveal publicly that Seroxat over the minimum dose of 20mg a day was ineffective and led to more side-effects. He now thinks the MHRA should follow the example of the US.

"In view of this decision by the conservative FDA, I think the MHRA must now immediately issue advice to people in the UK over suicidality in adults," he said.

"I fear they won't, because they have a reluctance to engage proactively with this issue, and also because they are concerned about the European licence." The drugs were licensed for the whole of Europe and it is likely that the MHRA would want to wait for a European consensus.

The FDA says that patients on the drugs must be more closely monitored for suicidal thoughts. Karen Barth Menzies, a lawyer with Baum Hedland in the US, which is pursuing legal claims against the companies, welcomed the FDA statement, but regretted that it had taken a decade of pressure to get the bold-print warnings manufacturers will now have to include on labelling.

"Through our litigation over the past 13 years, we've seen the internal documentation that shows the drug companies have known that their drugs can cause suicide and violence even before the drugs were approved for marketing," she said. "Moreover, both the FDA and drug companies have known that these drugs are only marginally effective in treating depression, thus the perception that the benefits outweigh the risks is based on misleading promotion of the drugs' benefits."

Special reports
Medicine and health

Useful links
British Medical Association
Department of Health
General Medical Council
Health on the Net Foundation
Institute of Cancer Research
Medical Research Council
NHS Direct
World Health Organisation




Printable version | Send it to a friend | Save story

 
 



UP

Guardian Unlimited Guardian Newspapers Limited 2004